Key facts
- China's medicine regulator approved Eli Lilly's orforglipron on November 12, 2026, Reuters reported.
- Orforglipron is an oral GLP-1 weight loss drug, according to the Gelonghui report.
- The approval covers long-term weight management in adults, the 10jqka report said, citing the National Medical Products Administration.
China's medicine regulator approved Eli Lilly's weight loss pill orforglipron, the regulator said on Thursday, according to a Reuters report dated November 12, 2026. The approval covers an oral treatment for long-term weight management in adults.
The regulator's approval makes orforglipron the first oral GLP-1 weight loss drug cleared in China, according to the Gelonghui report. The 10jqka report, citing the National Medical Products Administration, said the drug is indicated alongside diet and exercise for adults with a body mass index of 30 or above, or 27 to below 30 with at least one weight-related condition such as high blood pressure, abnormal blood lipids, high blood sugar, obstructive sleep apnea or cardiovascular disease.
Eli Lilly did not state pricing, launch timing or supply plans for the Chinese market in the accepted reports.